Antibiotics can effectively prevent intestinal cancer metastasis

Share This Post

Researchers from Harvard University found evidence in a new study that colon cancer cells carry certain bacteria when they metastasize to other organs in the body. The results of the study were published in the journal Science, and the team described their possible association with bacteria and their cause of colon cancer.

Previous research has shown that bacteria and tumor cells are present in various types of cancer, which makes some people in the medical community wonder whether they are the real cause of tumor formation. A bacterium called Fusobacterium nucleatum has been shown to exist in colon cancer cells. In this new study, the researchers wanted to know whether the same bacteria can be found in colon cancer tumor cells when these cancer cells have metastasized to other parts of the body.

To find out, the researchers collected tissue samples from patients with colon cancerIn the course of the research, they found that in many cases, the same bacterial strain exists in the tumor. Even if colon cancer cells have metastasized, the most common metastatic site of colon cancer is the liver, but there is no evidence to show that the bacteria in colon cancer cells , Present in the liver.

The researchers were very interested in this discovery. The researchers implanted tumors in healthy mice, so they found that those tumors with bacteria began to grow. Next, the research team tested the possibility of using antibiotics capable of killing F. nucleatum to treat colon cancer mice. They found that doing so actually slowed the growth of the tumor.

This discovery allows researchers to find a new direction against colon cancer, and hopes that further research can prove the effectiveness and safety of this method. 

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy